Regeneron Pharmaceuticals (NASDAQ:REGN) Releases Quarterly Earnings Results, Misses Expectations By $0.61 EPS

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) issued its quarterly earnings data on Tuesday. The biopharmaceutical company reported $8.22 earnings per share (EPS) for the quarter, missing the consensus estimate of $8.83 by ($0.61), Briefing.com reports. The business had revenue of $3.03 billion during the quarter, compared to analyst estimates of $3.40 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. Regeneron Pharmaceuticals's revenue for the quarter was down 3.7% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $9.55 earnings per share.

Regeneron Pharmaceuticals Stock Performance

REGN traded up $15.61 during trading on Friday, hitting $605.61. The stock had a trading volume of 1,606,415 shares, compared to its average volume of 745,022. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95. The company has a 50 day moving average price of $626.49 and a 200-day moving average price of $709.39. Regeneron Pharmaceuticals has a one year low of $525.99 and a one year high of $1,211.20. The firm has a market cap of $66.21 billion, a price-to-earnings ratio of 15.82, a P/E/G ratio of 2.34 and a beta of 0.44.

Regeneron Pharmaceuticals Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, June 6th. Stockholders of record on Tuesday, May 20th will be paid a dividend of $0.88 per share. The ex-dividend date of this dividend is Tuesday, May 20th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.58%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is currently 8.96%.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on REGN. Truist Financial lowered their price objective on shares of Regeneron Pharmaceuticals from $975.00 to $940.00 and set a "buy" rating for the company in a research report on Wednesday. JPMorgan Chase & Co. lowered their target price on Regeneron Pharmaceuticals from $1,100.00 to $1,000.00 and set an "overweight" rating for the company in a report on Monday, March 31st. TD Cowen reduced their price objective on Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a "buy" rating for the company in a research report on Tuesday, February 4th. Bank of America decreased their price objective on Regeneron Pharmaceuticals from $575.00 to $547.00 and set an "underperform" rating for the company in a report on Thursday, April 17th. Finally, The Goldman Sachs Group reduced their target price on shares of Regeneron Pharmaceuticals from $917.00 to $804.00 and set a "buy" rating for the company in a report on Wednesday. One analyst has rated the stock with a sell rating, five have assigned a hold rating, eighteen have given a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $892.60.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

An institutional investor recently raised its position in Regeneron Pharmaceuticals stock. Brighton Jones LLC increased its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 261.8% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 948 shares of the biopharmaceutical company's stock after purchasing an additional 686 shares during the period. Brighton Jones LLC's holdings in Regeneron Pharmaceuticals were worth $675,000 as of its most recent filing with the SEC. 83.31% of the stock is currently owned by institutional investors and hedge funds.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.